Kali Phos

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Kali Phos
Generic name: DIBASIC POTASSIUM PHOSPHATE
Manufacturer: Hylands Inc.
Product type: HUMAN OTC DRUG
SPL set ID: d398ba78-c986-9f9a-e053-2995a90ace53
SPL ID: efa53214-b2a7-cfd0-e053-2a95a90abbdf
Version: 2
Effective date: 2022-12-12
Source export date: 2026-09-28
Source partition: 6
Source file: https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/e0861bcde1444ef952820955caafc6f3fd29783e5ade07a13d933aa3336b399f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:43:04

Harmonized routes table
Harmonized routes
ORAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
brand name		Kali Phos	openfda.brand_name
generic name		DIBASIC POTASSIUM PHOSPHATE	openfda.generic_name
manufacturer name		Hylands Inc.	openfda.manufacturer_name
ndc	package	54973-4077-2	openfda.package_ndc
ndc	package	54973-4077-1	openfda.package_ndc
ndc	product	54973-4077	openfda.product_ndc
ndc11	package	54973407701	derived:openfda.package_ndc
ndc11	package	54973407702	derived:openfda.package_ndc
spl id		efa53214-b2a7-cfd0-e053-2a95a90abbdf	id
spl set id		d398ba78-c986-9f9a-e053-2995a90ace53	set_id
unii		CI71S98N1Z	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings Stop use and ask a doctor if ■ symptoms persist for more than 72 hours or worsen. ■ new symptoms occur. ■ redness or swelling is present. If pregnant or breastfeeding ask a health professional before use. Keep out of reach of children.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.